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Adulteration of Dietary Supplements by the
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Abstract: In the last few years, the consumption of dietary supplements, especially those having plants as ingredients,
has been increasing due to the common idea that they are natural products posing no risks to human health. In the
European Union and the United States, dietary supplements are legally considered as foods/special category of foods,
thus are not being submitted to any safety assessment prior to their commercialization. Among the issues that can
affect safety, adulteration by the illegal addition of pharmaceutical substances or their analogs is of major concern since
unscrupulous producers can falsify these products to provide for quick effects and to increase sales. This review discusses
the various classes of synthetic drugs most frequently described as being illegally added to dietary supplements marketed for
weight loss, muscle building/sport performance and sexual performance enhancement. Information regarding regulation
and consumption is also presented. Finally, several conventional and advanced analytical techniques used to detect and
identify different adulterants in dietary supplements and therefore also in foods, with particular emphasis on plant food
supplements, are critically described. This review demonstrates that dietary supplement adulteration is an emerging
food safety problem and that an effective control by food regulatory authorities is needed to safeguard consumers.
Keywords: adulteration, analogs, dietary supplements, food safety, pharmaceutical drugs, plant food supplements
Introduction
In the last few years, the consumption of dietary supplements,
in particular those labeled as being plant food supplements (PFS),
has been increasing worldwide. Since ancient times, botanicals
and botanical preparations have been used for health purposes,
either for nutritional objectives to maintain well-being and pre-
vent ailments or as medicines used to cure a disease or relieve its
symptoms (Eussen and others 2011). The use of plants is mainly re-
lated to their composition in different compounds that are known
to have physiological effects in humans, including major nutri-
ents, vitamins, minerals, and other biologically active substances
(Silano and others 2011). Besides being used as food and in tradi-
tional medicine, more recently, botanicals and preparations thereof
have also found several other applications including cosmetics,
homeopathic products, biocides, extraction of compounds for the
pharmaceutical industry, and as ingredients in dietary supplements
(Garcia-Alvarez and others 2014). In particular, during the last
few years botanicals have become increasingly available on world-
wide markets in the form of PFS, which are legally considered as
foods, both in the European Union (EU) and the United States
under Directive 2002/46/EC and the Dietary Supplement Health
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and Education Act (DSHEA), respectively, thus not requiring any
safety assessment prior to their commercialization. Because the
formulation of PFS includes plants or plant extracts, they are of-
ten advertised as being “natural” with many consumers perceiving
these products as being “healthier” and safer compared to con-
ventional pharmaceutical preparations. However, besides the risks
inherent to the consumption of botanicals, such as possible side
effects and interaction of biologically active phytochemicals with
prescription drugs, in the last few years different studies have been
reporting cases of PFS adulteration with different synthetic drugs
(pharmaceuticals or their analogs). This type of adulteration is a
major food safety and public health concern considering both the
massive growing consumption of PFS and the fact that consumers
are not aware of the risks associated with the possibility of phar-
maceutical drugs being illegally added. Therefore, several works
have been performed in the last decade reporting the develop-
ment and application of new and advanced techniques for the
detection of adulterants in dietary supplements, with special focus
on PFS. This review intends to provide an overview on recent
information regarding this subject, comprised of data on the most
frequently reported adulterants in PFS and the currently available
analytical techniques used for the detection and identification of
synthetic drugs illegally added to these products. General infor-
mation about legislation and consumption of dietary supplements
(including PFS) is also presented. Since PFS are frequently catego-
rized according to their advertised purpose, this review will focus
on the ones used for weight loss, muscle building/sport perfor-
mance, and sexual performance enhancement purposes, as they
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represent the majority of consumed PFS, thus the most prone to
be adulterated.
Regulation, Consumption, andAdulteration of Dietary
Supplements
Regulation on dietary supplements (including PFS)
In the EU, food supplements (which includes PFS) are regu-
lated by the Directive 2002/46/EC which defines these products
as being “ . . . foodstuffs the purpose of which is to supplement
the normal diet and which are concentrated sources of nutri-
ents or other substances with a nutritional or physiological effect,
alone or in combination, marketed in dose form, namely forms
such as capsules, pastilles, tablets, pills and other similar forms,
sachets of powder, ampoules of liquids, drop dispensing bottles
and other similar forms of liquids and powders designed to be
taken in measured small quantities.’’ This Directive also speci-
fies “nutrients” as being vitamins and minerals and establishes the
maximum and minimum levels for the allowed compounds, yet
it does not mention what can, or cannot, be accepted as being
“other substances with nutritional or physiological effect.” Thus,
several different substances are generally accepted as being in-
cluded in this definition such as amino acids, enzymes, pre- and
probiotics, essential fatty acids, and botanicals or botanical ex-
tracts, with their use frequently depending on national legislation
(Silano and others 2011). The lack of specification and harmo-
nization among the different EU countries regarding the usage of
botanicals or botanical extracts in dietary supplements results in
discrepancies among states with the inclusion of some botanicals
in PFS being allowed in some countries and prohibited or non-
regulated in others. Additionally, based on the current legislation
in EU, botanicals and extracts thereof can be used either in PFS
or as traditional herbal medicines (regulated by the Directive for
traditional medicinal products (Directive 2004/24/EC)), with the
distinction between both being somehow blurred, as the border-
line between food and medicinal uses is often established based on
national habits and interpretation of definitions in legal provisions
(Silano and others 2011). Being considered as foods in the EU,
PFS are subjected to the dispositions of the General Food Law
(Regulation (EC) 178/2002), with the responsibilities for food
safety issues mainly relying on food business operators. This also
implies that PFS must comply with other food legislation such as
hygiene regulations (Regulation (EC) 852/2004), maximum level
of contaminants (Regulation (EC) 1881/2006), and novel foods
regulation (Regulation (EC) 258/97) among others. Despite the
wide range of regulations, food safety problems may arise in differ-
ent member states, leading the EU to operate a rapid alert system
for food and feed (RASFF). The RASFF provides the supervisory
authorities with a quick and efficient mechanism for exchanging
knowledge on the notifications issued by the different EUmember
states every time a food presents a serious risk to public health due
to contamination, adulteration, or lack of framing in the above-
mentioned laws. With this information, the member states are
able to take immediate action, warning consumers, and causing
products withdrawal from the market (Petroczi and others 2011).
The RASFF database can be searched by food type and product
category in which “Dietetic foods, food supplements, fortified
foods” is included.
In the United States, both finished dietary supplements (includ-
ing PFS) and their ingredients are regulated by the Food and Drug
Administration (FDA). However, they are covered by a regulatory
framework signed into law in 1994, the “Dietary Supplement
Health and Education Act of 1994” (DSHEA), which recognizes
dietary supplements as a separate category of foods and establishes
its own requirements for safety and labeling, thus limiting FDA’s
ability to regulate supplements. The DSHEA states that a dietary
supplement is a product (other than tobacco) intended to sup-
plement a diet, as long as it bears or contains 1 or more of the
following dietary ingredients: vitamins; minerals; herbs or other
botanicals; amino acids; dietary substances used by man to sup-
plement a diet by increasing the total dietary intake; concentrates,
metabolites, constituents, extracts, or a combination of the ingre-
dients referred to above, and is intended to be taken by mouth as a
pill, capsule, tablet, or liquid (USA 1994). Furthermore, according
to DSHEA, this type of product is not represented for use as a con-
ventional food or as a sole item of a meal or the diet and should be
labelled as a dietary supplement (USA 1994). Additionally, under
this framework, a company is responsible for determining that the
dietary supplements it manufactures or distributes are safe and that
any claims made are substantiated by adequate evidence (Silano
and others 2011). In the U.S., similar to what happens in the EU,
dietary supplements do not require any approval from FDA before
being introduced in the market. Manufacturers do not have to
provide evidence for the safety and effectiveness of the products,
but they are prohibited to market unsafe or ineffective products
(Rapaka and Coates 2006). Nevertheless, if a dietary supplement
includes in its formulation any ingredients marketed after 1994,
which are considered as “new ingredients,” the manufacturer must
first notify FDA and provide information regarding reasonable ev-
idence that it is safe for human use (Rapaka and Coates 2006).
According to Wheatley and Spink (2013), DSHEA significantly
weakened FDA’s authority over dietary supplements and created
opportunities for consumer deception, in particular in what con-
cerns imported supplements. The recent review of Silano and
others (2011) can be consulted for more detailed information re-
garding regulations applicable to PFS, including in other countries
not mentioned in this paper, and the review by Wheatley and
Spink (2013) for more information regarding dietary supplements
in the United States.
Consumption of dietary supplements (with particular em-
phasis on PFS)
Over the last decade, it is undeniable the existence of notori-
ous growth in the consumption of dietary supplements. Among
these, PFS consumption showed a strong increase, with its highest
consumption records occurring in the U.S. and EU (Egan and
others 2011). The increased acceptance of these types of product
by different consumer groups has been associated with a variety
of factors including (1) a rising mistrust in conventional medicine
and pharmaceutical drugs together with a higher demand and in-
terest for alternative therapies, (2) the perception that “natural” is
“healthy” and that plant products are safe, (3) a rising tendency
for self-medication aiming for increased control over one’s own
health and decisions that may affect it (Ritchie 2007; Egan and
others 2011; Vargas-Murga and others 2011).
Dietary supplements are used by the population in general for
a variety of purposes, including for balancing the diet, to com-
pensate for the lack of nutrients or exercise or unhealthy lifestyle,
health maintenance, to prevent chronic diseases, improve appear-
ance, improve wellness including mental conditions, for sexual
performance enhancement and sports performance enhancement,
among others (Egan and others 2011; Petroczi and others 2011).
Different studies regarding the consumption of dietary supple-
ments have been carried out, most of them focusing on spe-
cific population groups such as children, pregnant women, the
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elderly, individuals with chronic diseases, cancer patients, and
athletes (Petroczi and others 2011; Vargas-Murga and others 2011).
However, most information on the prevalence of the use of di-
etary supplements in general, and the intake of PFS in particular,
come from the U.S. with data being obtained as part of large sur-
veys, such as the Natl. Health and Nutrition Examination Surveys
(NHANES), the Health and Diet Surveys, and the Natl. Health
Interview Surveys (NHIS) (Egan and others 2011; Garcia-Alvarez
and others 2014). Based on data from NHANES (2003 to 2004
and 2005 to 2006), it was estimated that approximately 49% of
the U.S. population used dietary supplements, with 14% report-
ing the use of PFS, while in NHIS 2007, almost 18% of the
surveyed adults reported the use of PFS. In 2002, a prevalence
study regarding the usage of nonvitamin nonmineral supplements
among 1000 students from a U.S. university with average age of
26-y-old, showed that more than 26% used that kind of supple-
ments with ginseng, echinacea, protein/amino acids, and gingko
biloba being the most frequently reported (Perkin and others
2002). In the EU, as part of the FP7 project PlantLIBRA, a
retrospective survey concerning the type and frequency of PFS
consumption among 6 EU countries (Finland, Germany, Italy,
Romania, Spain, and the United Kingdom) was recently reported
(Garcia-Alvarez and others 2014). The study, which included a to-
tal of 2359 participants, showed that almost 19% used at least 1 PFS,
with higher values being observed in Italy (22.7%) and lower ones
in Finland (9.6%), and that PFS including ginkgo biloba, evening
primrose, and artichoke, in the form of capsules or tablets, were
the most frequently used.
Although the factors leading to PFS consumption may vary
according to demographic and health factors, among others, the
information available in the literature regarding the characteristics
of PFS consumers seem to show that, in general, higher consump-
tion is found for women, older adults, individuals generally having
a higher education and socioeconomic level, being more likely to
self-report their health status as being “good,” being physically
active while being less likely to smoke (Schaffer and others 2003;
Radimer and others 2004; Nielsen and others 2005; Egan and
others 2011; Garcia-Alvarez and others 2014). A high intake of
dietary supplements (including PFS) is also reported to take place
among athletes in order to improve their training performance
(Petroczi and others 2008, 2011; Kiertscher and DiMarco 2013).
Adulteration in dietary supplements
With an increasing consumption of dietary supplements, safety
in production and marketing, namely in what concerns the quality
and levels of physiologically active ingredients in these products as
well as labeling compliance, is a general concern for the different
stakeholders worldwide including consumers, health professionals,
and regulators (Sullivan and Crowley 2006). In particular, differ-
ent safety issues have emerged regarding PFS, which are consid-
ered derivatives from plants and therefore are frequently labelled
as "natural" products, thereby transmitting a false sense of secu-
rity to the consumer since much toxicity is embedded in nature
(Liang and others 2006; Di Lorenzo and others 2014). Among
such issues, adulteration of PFS, including either the addition of
illegal substances or the intentional swap or misidentification of
plant material, is a major concern. Considering the economic
value associated with the global trade of dietary supplements (in
the United States, it is estimated that consumers spend over $20
billion each year on these products), they are very prone to be
adulterated for economic reasons and profit increases (Wheatley
and Spink 2013). One of such adulterations encompasses the ille-
gal addition of synthetic drugs since unscrupulous producers can
augment dietary supplements to provide for quicker effects. In
fact, for some products as, for example, weight-loss dietary sup-
plements, consumers tend to quit using those products if they
don’t realize any initial effects. On the contrary, if the supplement
quickly succeeds in providing the desired results, more units are
likely to be sold, thus increasing the seller’s profit.
Several studies performed over the last decade have been show-
ing intentional adulteration of dietary supplements by the addition
of pharmaceutical drugs, especially in the case of PFS as they have a
more complex matrix, thus making adulterant detection more dif-
ficult to accomplish. Pharmaceutical adulterants include appetite
suppressors, stimulants, antidepressants, anxiolytics, diuretics, and
laxatives in weight-loss PFS, phosphodiesterase type-5 enzyme
(PDE-5) inhibitors in sexual performance enhancement, and an-
abolic steroids and prohormones in supplements used for muscle
building/sports performance enhancement. An additional prob-
lem concerns the use of analogs of those substances, for which no
pharmacological studies are available, and also the use of counter-
feit drugs of doubtful quality.
As referred to in the previous sections, being legally considered
as foods in several countries, dietary supplements (including PFS)
do not require any kind of permission to be placed on the market,
but the legal responsibility for their safety lies with the business
operators. Consequently, in the EU several phytoformulations are
being sold under the guise of PFS allowing them to circumvent
the requirements and official registration procedure needed if they
were considered as being traditional medicinal products. Addi-
tionally, nowadays PFS are widespread in the global market, being
easily accessible to consumers in supermarkets, drugstores, natural
health/food stores, herbal shops, and gyms possible to be pur-
chased through television sales and online by using the Internet.
In the last decade, the spread of dietary supplements coming from
the black market has also suffered a significant increase (Geyer and
others 2008; Petroczi and others 2011; Gilard and others 2015;
Odoardi and others 2015).
In the U.S., under the Dietary Supplement and Nonprescrip-
tion Drug Consumer Protection Act, signed into law in December
2006, the manufacturer, packer, or distributor of a dietary supple-
ment, whose name appears on the label of a dietary supplement
marketed in the U.S., must report to FDA, within 15 d, any se-
rious adverse events (events that result in death, a life-threatening
experience, hospitalization, a persistent or significant disability or
incapacity, a congenital anomaly or birth defect, or requires, based
on a reasonable medical judgment, a medical or surgical interven-
tion to prevent any of the referred outcomes) that are reported to
them by consumers or health care professionals (FDA 2015c). If
the adverse events are not considered serious in accordance with
the 2006 act, the firm can still complete and submit a voluntary
adverse events report (AER) form at its discretion. FDA reviews
all AERs in a postmarket surveillance effort to track safety is-
sues that require intervention, however an AER by itself does not
demonstrate a causal relationship between the dietary supplement
and the reported health problem (GAO 2013). Consumers and
health professionals are strongly encouraged to voluntary report
adverse effects to FDA since dietary supplements adulterated with
active pharmaceutical drugs or their analogs can become appar-
ent through AER surveillance, thus assisting FDA in identifying
potential safety concerns.
Despite the potentially serious health risks, very little is known
about the prevalence or common adverse effects of dietary sup-
plements adulterated by the illegal addition of pharmaceuticals. A
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2007 retrospective study concerning patients who were referred
to the Hospital Authority Toxicology Reference Laboratory of
Hong Kong from 2004 to 2006, described a positive result for
the presence of pharmaceutical drugs or their analogs (either on
urine samples, on the consumed dietary supplement, or in both)
for 28 individuals from a total of 42 patients suspected to have
clinical problems related to the use of weight-loss products (Yuen
and others 2007). The authors also described the identification
of sibutramine, fenfluramine and a fenfluramine analog in 3 slim-
ming products, and the hospitalization of 4 patients after taking
those products (Yuen and others 2007). More recently, Cohen
and others (2012) assessed the prevalence of use and associated
side effects of Pai You Guo, a weight-loss dietary supplement
manufactured in China that was found to be adulterated, by per-
forming a cross-sectional study using an anonymous questionnaire
distributed among Brazilian women living in a U.S. community.
From the 565 valid surveys, 130 respondents confirmed using this
supplement, corresponding to an overall prevalence of Pai You
Guo use of 23% (Cohen and others 2012). The vast majority of
women using this supplement (85%) reported experiencing at least
1 side effect during use, the most frequent being dry mouth (59%),
anxiety (29%) and insomnia (26%) (Cohen and others 2012). Even
though the authors did not analyzed any sample of the PFS used
by those women, the FDA has previously found sibutramine in
Pai You Guo. As a consequence, in late 2009, the FDA take mul-
tiple steps including a safety alert to consumers and a recall of the
product due to serious safety concerns. Despite this, in the study
of Cohen and others (2012) 61% of users purchased the dietary
supplement after the FDA recall and none of the respondents were
aware of the FDA alert. Subsequently, to investigate if supplements
still on sale after FDA recalls are free of adulterants, Cohen and
others (2014) evaluated the presence of banned drugs in 27 di-
etary supplements purchased at least 6 mo after being recalled.
The authors found that 18 of those recalled dietary supplements
still available for purchase remained adulterated, with 12 prod-
ucts containing the same adulterant previously identified by the
FDA and 6 products containing a different analog, or the same
compound previously identified added with a new adulterant.
For the mentioned reasons, there has been a recent major in-
terest in the development of analytical techniques aimed at an
accurate, quick, and effective screening of illegal substances in di-
etary supplements, with special focus on PFS, in order to provide
adequate tools for regulatory agencies to control the existence of
fraud by detecting tainted PFS. In the following sections, informa-
tion regarding the substances most frequently used to adulterate
different PFS are presented from published studies focusing on the
evaluation of PFS samples, as well as the techniques used to detect
those substances.
PFS Often Adulterated
Weight-loss supplements
Overweight and obesity are major risk factors for several chronic
diseases and have been recognized by the World Health Organi-
zation as an increasing public health issue affecting millions of
individuals, especially in Western developed countries. Addition-
ally, for health reasons today’s society strongly promotes having a
normal weight and a slim figure. The loss of weight or the mainte-
nance of an ideal weight are both commonly associated with diet
and exercise, often requiring significant changes in eating behavior
and lifestyle (Wing and Phelan 2005). In the search for alterna-
tives to a quicker weight loss and to simultaneously avoid lifestyle
changes, people are increasingly resorting to the so-called "quick-
fix" slimming agents (Tang and others 2011). As a result, several
PFS are currently being sold with alleged weight-loss promise.
Since these products have plants or plant extracts in their com-
position, they are often advertised as containing “purely natural
ingredients,” which is generally perceived by many consumers
as having no risks and being safer products than pharmaceutical
drugs. However, they can cause adverse reactions or interfere with
conventional pharmaceutical therapies, even though both cases are
considered as uncommon by sellers (Di Lorenzo and others 2014).
More importantly, recent studies have shown that weight-loss PFS
are frequently found to be adulterated by the illicit addition of
synthetic drugs (Table 1). Since the sale of PFS advertised for
weight loss has become a very lucrative business, manufacturers
can be tempted to increase profits by doping PFS with drugs in
order to achieve quicker effects and to advertise the effective-
ness of their products (Chen and others 2009; Tang and others
2011; Deconinck and others 2012a). The drugs most generally
associated with weight-loss PFS adulteration include anorexics
(such as sibutramin, orlistat, diethylpropion (amfepramone), ri-
monabant, fenproporex, phentermine, and mazindol, and so on)
but also stimulants (ephedrine, norephedrine, and synephrine),
anxiolytics (mainly benzodiazepines such as diazepam), antide-
pressants (fluoxetine, sertraline), diuretics (such as furosemide and
hydrochlorothiazide), and laxatives (including phenolphthalein).
Several of these drugs are considered by regulatory agencies
as being controlled substances or prescription drugs and others
were banned/removed because of their adverse effects in humans
(De Carvalho and others 2011). Of these substances/adulterants,
the most frequently used are anorexics derived from amphetamines
(De Carvalho and others 2011), with sibutramine being the most
commonly detected in PFS. Sibutramine is considered an anorexic
structurally related to amphetamines; it acts as a neurotransmitter
reuptake inhibitor, reducing the reuptake of serotonine, nore-
pinephrine, and noradrenalin, resulting in higher concentrations
of these compounds at the synaptic clefts, thus leading to a reduc-
tion in appetite (Deconinck and others 2014). This compound
was approved by FDA in 1997 and was legally prescribed and
sold for the treatment of obesity until 2010 when Abbott Labo-
ratories (Ill., U.S.A.) voluntarily withdrew sibutramine from the
market due to the high risk of heart attacks and strokes, especially
in patients with a history of cardiovascular disease (Csupor and
others 2013). In the same year, the European Medicines Agency
(EMA) issued a statement for the removal of sibutramine from the
European market considering that the drug’s benefits did not jus-
tify the potential risk of heart attacks (EMA 2010). Even though
sibutramine has been banished from the EU and U.S. markets,
both scientific studies and regulatory agency controls show that
this drug continues to be fraudulently added to PFS. According
to the FDA list of tainted dietary supplements, from a total of 416
public alerts launched between 2010 and 2015, 37% corresponded
to adulterated weight-loss products, from which most cases (87%)
involved the illegal addition of sibutramine (FDA 2015a). In the
same period, the EU rapid communication system on food and
feed (RASFF) notified that 64 weight-loss dietary supplements
imported from different countries (mainly China and the United
States, but also from Thailand, the Philippines, the Netherlands,
the United Kingdom, Kosovo, and Australia) were contaminated
with sibutramine (RASFF 2015). This drug was also reported as
the most frequently used anorexic in a 2009 study (before it was
withdrawn) after the evaluation of 105 PFS, from which 35 sam-
ples were shown to contain adulterant slimming agents (Chen and
others 2009). Since the illegal addition of sibutramine is known to
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be recurrent in dietary supplements, this drug is generally included
in the set of substances screened as adulterants in weight-loss PFS
(Table 1).
Other amphetamine derived anorexics known to induce ap-
petite loss but also having several side effects, such as fenpro-
porex and amfepramone, have also been described as adulterants
in slimming phytopharmaceutical products (De Carvalho and oth-
ers 2011). As of 2010, several RASFF notifications were also made
for products containing stimulants such as the alkaloids ephedrine
(3 notifications) and synephrine (26 notifications). Among other
compounds used to adulterate is phenolphthalein, a drug used
as laxative and banned due to carcinogenicity concerns: it is fre-
quently listed in public notifications from the FDA and RASFF.
Since 2010 and considering a total of 155 weight-loss products
listed by FDA as being adulterated, 9 products were shown to con-
tain phenolphthalein and 48 products to contain this compound
in combination with other drugs, such as sibutramine. In the same
period, a total of 19 incidents were reported in RASFF for the
detection of phenolphthalein in dietetic foods, food supplements,
and fortified foods. Recently, the FDA also reported the presence
of the antidepressant fluoxetine in dietary supplements. Anxiolyt-
ics, such as the 2 benzodiazepines diazepam and flurazepam, are
also described as being associated with weight-loss PFS since they
help to reduce anxiety, which is common in obese patients, while
simultaneously covering the stimulating effects caused by added
anorexics (De Carvalho and others 2011).
Body-building and athletic performance enhancement sup-
plements
Dietary supplements are used by a large percentage of general
consumers. Nevertheless, evidence suggests that an even larger us-
age rate occurs among athletes, although consumption prevalence
varies with the type of sport, gender, and level of competition
(Maughan and others 2011). Most athletes are very scrupulous
with their body image and often choose to maintain certain re-
strictive diets, avoiding some foods in order to achieve a desired
physical constitution, which is considered by some athletes as an
important factor for their performance improvement. Such diets
are often very strict and sometimes unbalanced, therefore leading
to a nutritional failure of essential vitamins and minerals that can
endanger both performance and health. To fulfill their nutritional
needs, athletes may use a dietary supplement in order to diminish
micronutrient deficits. However, regardless of their nutritional sta-
tus, some athletes believe that taking supplements improves body
appearance and physical performance, thus resorting to dietary
supplements even if they are not needed (Kiertscher and DiMarco
2013).
Besides competitive sports, where the use of dietary supplements
is considered to be widespread, these products are also commonly
used by recreational gym users and amateur athletes (Goston and
Correia 2010). Among dietary supplements, vitamin and mineral
supplements are possibly the most consumed ones as they are
generally perceived as being safe/harmless, though many PFS are
also used. In particular, the so-called “fat-burning” and weight-
loss products are considered to be PFS that are extremely popular
among athletes (Maughan and others 2011).
Recent studies have shown that a wide range of substances can
be present in dietary supplements advertised for body building
and athletic performance enhancement, such as anabolic agents,
stimulants, and anorexics, these often found in PFS (Maughan
and others 2011). The 1st cases concerning the presence of
anabolic androgenic steroids (AAS, also known as prohormones)
in dietary supplements were reported in 1999 (Geyer and others
2008). In subsequent years, different studies were performed,
including the analysis of a large number of dietary supplements
acquired in the U.S. and several European countries, clearly
demonstrating that some products contained hormones or
prohormones that were not declared on the label (Maughan
2005). However, most of these substances were found at very low
levels and in varying concentrations for the same product, thus
suggesting a cross-contamination instead of fraudulent admixtures.
Nevertheless, it was demonstrated that the consumption of such
supplements taken in the recommended doses could result in
positive antidoping controls tests. This entails a major risk for
high-level competition athletes since the strict liability principle
applied by the World Anti-Doping Agency (WADA) does not
distinguish between deliberate and inadvertent doping due to
food supplements consumption, with all kinds of responsibility
lying with the athlete taking the supplement (WADA 2015). In
other cases, high amounts of WADA-prohibited substances, such
as methandienone, have also been detected, sometimes in amounts
considerably higher than the normal therapeutic doses, and these
could jeopardize an athlete’s health (Maughan and others 2011).
A wide range of stimulants, steroids, and other agents cur-
rently included on WADA’s prohibited list have been identified
as adulterants in dietary supplements. According to WADA, these
substances are described as being performance enhancing drugs
(PEDs), which are defined as being any pharmacological substance
listed in the World Anti-Doping Code, or that has not been ap-
proved by a governmental regulatory health authority for human
therapeutic use. Adulteration of dietary supplements with PEDs
has been reported by several authors (Pipe and Ayotte 2002; Geyer
and others 2004; Maughan 2005; van der Merwe and Grobbelaar
2005), and this can lead to a positive antidoping test. Besides sub-
stances with no current approval for human therapeutic use by any
governmental regulatory health authority (generally considered as
“designer” drugs), WADA’s prohibited list includes an enormous
diversity of chemicals, namely anabolic agents (AAS, clenbuterol,
selective androgen receptor modulators, tibolone, zeranol, zilpa-
terol), peptide hormones, growth factors, and related substances
(growth hormone, erythopoietin, chorionic gonadotropin),
β-2 agonists, hormones, and metabolic modulators (aromatase
inhibitors and selective estrogen receptor modulators), diuretics,
and certain masking agents (such as acetazolamide, carmerone,
indaparid, and plasma expanders). Moreover, many substances
are included that are prohibited in-competition, namely stim-
ulants (amfepramone, meferox, pseudoephedrine, sibutramine),
narcotics (such as buprenorphine, dextromoramide, methadone,
morphine, oxycodone), cannabinoids, and glucocorticosteroids
(WADA 2014). Among the mentioned substances, the use of
new/modified or “designer” steroids (such as prostanozol, methas-
terone, andostatrienedione, among others) is of higher concern
because so little is known about their pharmacology and possible
side effects (Geyer and others 2008).
When weighting the risks and advantages of using dietary sup-
plements, in particular those purchased from “shody” sources such
as InternetWeb sites selling all kinds of “natural” products, athletes
should consider the possibility that some of the above-mentioned
substances can be found in dietary supplements, and in PFS in
particular, most often to potentiate the "performance enhancing"
effect advertised in the product. Those substances can cause sec-
ondary effects or drug interactions with pharmaceutical medicines
or with the botanicals’ active substance and, in the case of competi-
tion athletes, usage may lead to their detection in antidoping tests.
C© 2015 Institute of Food Technologists® Vol. 15, 2016  Comprehensive Reviews in Food Science and Food Safety 49
Dietary supplements adulteration . . .
Ta
bl
e
2–
Su
m
m
ar
y
of
st
ud
ie
s
pe
rf
or
m
ed
on
th
e
an
al
ys
is
of
st
er
oi
d
ad
ul
te
ra
nt
s
in
di
et
ar
y
su
pp
le
m
en
ts
an
d
m
et
ho
do
lo
gi
es
.
A
du
lt
er
an
ts
of
in
te
re
st
Fo
rm
ul
at
io
n
ty
pe
Sa
m
pl
e
pr
ep
ar
at
io
n
M
et
ho
d
A
du
lt
er
at
ed
sa
m
pl
es
/
to
ta
l
sa
m
pl
es
Re
fe
re
nc
e
25
A
na
bo
lic
st
er
oi
ds
So
lid
nu
tr
iti
on
al
su
pp
le
m
en
ts
:
pr
ot
ei
n
co
nc
en
tr
at
e
an
d
cr
ea
tin
e
m
on
oh
yd
ra
te
Sa
m
pl
e
ex
tr
ac
te
d
w
ith
et
hy
la
ce
ta
te
;
cr
ud
e
ex
tr
ac
ti
sp
ur
ifi
ed
us
in
g
di
sp
er
si
ve
so
lid
-p
ha
se
ex
tr
ac
tio
n
(S
PE
)w
ith
pr
im
ar
y
se
co
nd
ar
y
am
in
e
(P
SA
)a
ss
or
be
nt
G
C
×
G
C-
TO
F
M
S
–
St
ep
an
an
d
ot
he
rs
(2
00
8)
49
A
na
bo
lic
co
m
po
un
ds
Ca
ps
ul
es
,t
ab
le
ts
an
d
liq
ui
ds
(s
om
e
la
be
lle
d
as
co
nt
ai
ni
ng
pr
oh
or
m
on
es
)
Sa
m
pl
e
ex
tr
ac
te
d
tw
ic
e
w
ith
m
et
ha
no
l,
ce
nt
rif
ug
ed
,e
va
po
ra
te
d
to
dr
yn
es
s,
re
di
ss
ol
ve
d
m
et
ha
no
l
an
d
10
0-
fo
ld
di
lu
tio
n
in
m
et
ha
no
l/
w
at
er
(6
5/
35
,v
/
v)
LC
–M
S/
M
S
11
/
19
V
an
Po
uc
ke
an
d
ot
he
rs
(2
00
7)
11
A
na
bo
lic
an
dr
og
en
ic
st
er
oi
ds
Ca
ps
ul
es
,t
ab
le
ts
,
po
w
de
rs
,fl
ui
ds
Sa
m
pl
es
ex
tr
ac
te
d
w
ith
m
et
ha
no
l,
ce
nt
rif
ug
ed
,e
va
po
ra
te
d
to
dr
yn
es
s,
so
di
um
hy
dr
ox
id
e
so
lu
tio
n
0.
1
M
an
d
n-
pe
nt
an
e
ad
de
d
to
th
e
re
si
du
e,
sh
ak
e
an
d
ce
nt
rif
ug
e;
tr
an
sf
er
n-
pe
nt
an
e
la
ye
r,
ad
d
m
et
ha
no
l/
w
at
er
so
lu
tio
n
(9
5:
5,
v/
v)
;s
ha
ke
an
d
ce
nt
rif
ug
e;
di
sc
ar
d
n-
pe
nt
an
e
la
ye
r,
ad
d
m
et
ha
no
lic
so
lu
tio
n
of
1-
(N
,N
-
di
is
op
ro
py
la
m
in
e)
-a
lk
an
es
,
ev
ap
or
at
e
to
dr
yn
es
sa
nd
re
si
du
e
its
de
riv
at
iz
at
ed
G
C-
M
S
94
/
63
4
G
ey
er
an
d
ot
he
rs
(2
00
8)
U
nk
no
w
n
an
dr
og
en
sa
nd
an
dr
og
en
de
riv
at
iv
es
N
ot
re
fe
rr
ed
(4
he
rb
al
m
ix
tu
re
sa
nd
4
sp
or
ts
up
pl
em
en
ts
)
Sa
m
pl
e
so
ni
ca
te
d
w
ith
m
et
ha
no
la
nd
so
di
um
ac
et
at
e
bu
ff
er
(0
.2
5
M
;p
H
4.
8)
,c
en
tr
ifu
ge
d
an
d
ac
et
ic
ac
id
(4
.0
M
)a
dd
ed
to
su
pe
rn
at
an
t
(r
ea
ch
in
g
pH
4.
8)
;S
PE
pu
rifi
ca
tio
n
(1
st
on
C1
8
ca
rt
rid
ge
fo
llo
w
ed
by
2n
d
SP
E
on
Is
ol
ut
e
N
H
2
ca
rt
rid
ge
),
el
ua
te
ev
ap
or
at
ed
to
dr
yn
es
s
bi
oa
ss
ay
-g
ui
de
d
fr
ac
tio
na
tio
n
co
m
bi
ne
d
w
ith
U
H
PL
C/
TO
FM
S
5/
8
(c
om
po
un
ds
w
er
e
te
nt
at
iv
el
y
id
en
tifi
ed
)
Pe
te
rs
an
d
ot
he
rs
(2
01
0)
88
St
er
oi
ds
Ta
bl
et
s,
ca
ps
ul
es
or
po
w
de
r
Sa
m
pl
e
ex
tr
ac
te
d
w
ith
et
hy
l
ac
et
at
e/
ac
et
ic
ac
id
(9
9.
9:
0.
1,
v/
v)
,c
en
tr
ifu
ge
d,
up
pe
rl
ay
er
el
ut
ed
th
ro
ug
h
N
H
2
SP
E,
el
ua
te
ev
ap
or
at
ed
to
dr
yn
es
s,
re
si
du
e
di
ss
ol
ve
d
in
m
ob
ile
ph
as
e
an
d
ce
nt
rif
ug
ed
(U
ltr
af
re
e
R©
-M
C
ce
nt
rif
ug
al
,0
.2
2
μ
m
,M
ill
ip
or
e)
U
PL
C–
M
S
6/
8
Be
cu
e
an
d
ot
he
rs
(2
01
1)
A
nd
ro
ge
ni
c
an
d
es
tr
og
en
ic
(d
es
ig
ne
r)
st
er
oi
ds
N
ot
re
fe
rr
ed
Sa
m
pl
e
ex
tr
ac
te
d
(u
ltr
as
on
ic
ba
th
an
d
he
ad
-o
ve
rh
ea
d
m
ix
in
g)
w
ith
m
et
ha
no
la
nd
so
di
um
ac
et
at
e
(1
2.
5
m
M
,p
H
4.
8)
,c
en
tr
ifu
ge
d,
su
pe
rn
at
an
td
ilu
te
d
5
tim
es
w
ith
H
BS
-E
P
bu
ff
er
bi
oa
ffi
ni
ty
LC
-M
S
sc
re
en
in
g
co
up
le
d
to
ch
ip
-
U
PL
C(
N
an
oT
ile
)-Q
-
To
F-
M
S
8/
22
A
qa
ia
nd
ot
he
rs
(2
01
3)
35
A
na
bo
lic
st
er
oi
ds
an
d
cl
em
bu
te
ro
l
Po
w
de
rs
,c
ap
su
le
s,
en
er
gy
ba
rs
an
d
ta
bl
et
s
Sa
m
pl
e
di
ss
ol
ve
d
in
m
et
ha
no
l,
ev
ap
or
at
ed
to
dr
yn
es
s,
di
lu
te
d
in
so
di
um
hy
dr
ox
id
e
so
lu
tio
n,
ex
tr
ac
te
d
w
ith
pe
nt
an
e/
et
hy
l
et
he
r9
:1
LC
-H
RM
S
in
A
PC
I
m
od
e
16
/
30
(s
om
e
sa
m
pl
es
w
ith
m
ul
tip
le
co
m
po
un
ds
)
O
do
ar
di
an
d
ot
he
rs
(2
01
5)
50 Comprehensive Reviews in Food Science and Food Safety  Vol. 15, 2016 C© 2015 Institute of Food Technologists®
Dietary supplements adulteration . . .
Different studies recently available in the literature have shown
the presence of anabolic steroids and designer drugs in dietary
supplements, such as androstenedione, 5-androsten-3β-ol-17-one
(dehydroepiandrosterone; DHEA), methandienone, testosterone
esters, androst-4-ene-3β-17β-diol, boldenone, among others
(Geyer and others 2008; Becue and others 2011; Aqai and others
2013; Odoardi and others 2015). Table 2 shows a compilation
of studies reporting the presence of illegal substances in dietary
supplements. Additionally, regulatory agencies have also reported
the presence of adulterants in such products advertised for body
building/athletic performance enhancement. In the last 5 y, from
a total of 416 public notifications issued by FDA, 18 concerned
the presence of steroids or aromatase inhibitors in muscle build-
ing products (FDA 2015a). Although corresponding only to 4.3%
of the total notifications, it should be noticed that there is no
information regarding the total number of samples analyzed by
type of supplement (weight loss, sexual enhancement, or muscle
building).
Sexual performance enhancement supplements
Erectile dysfunction (ED) is a disease that affects 150 million
men worldwide (Schramek and others 2014) being characterized
by the inability to create or maintain penile erection during sexual
activity. The treatments currently known for this problem en-
compasses the administration of PDE-5 inhibitors drugs. These
compounds act by inhibiting the mentioned enzyme, which is
responsible for the degradation of cyclic guanosine monophos-
phate (cGMP) to guanosine monophosphate (GMP), thus causing
a rise of cGMP levels resulting in smooth muscle relaxation of
helicine arteries followed by an increase of blood, thus enhancing
normal erectile function (Codevilla and others 2013). Presently,
the PDE-5 inhibitors legally commercialized worldwide are silde-
nafil citrate (Viagra
R©
), tadalafil (Cialis
R©
), vardenafil hydrochloride
(Levitra
R©
), udenafil (Zydena
R©
), mirodenafil (Mvix
R©
), lodenafil
carbonate (Helleva
R©
), and avanafil (Stendra
R©
in the United States
or Spedra
R©
in EU) (Patel and others 2014). However, in theUnited
States and EU only sildenafil, tadalafil, vardenafil, and avanafil are
approved by the competent authorities (FDA and EMA, respec-
tively) for the treatment of ED (EMA 2015; FDA 2015b). The
side effects of prescription PDE-5 inhibitors and possible inter-
actions with other drugs are well documented. These drugs can
cause headaches, flushing, dyspepsia, nasal congestion, and visual
disorders, and because they were shown to potentiate the hy-
potensive effects of nitrates and α-blockers, the concomitant use
of PDE-5 inhibitors with such drugs should be avoided (Gur and
others 2013). Moreover, since sildenafil, tadalafil, and vardenafil
are mainly metabolized by the cytochrome P450 3A4 pathway,
drugs that inhibit this pathway may decrease metabolism of PDE-
5 drugs and increase their plasma concentrations (Schwartz and
others 2010).
During the last few years, the demand for PDE-5 inhibitors has
been increasing worldwide, not only for treating patients with ED
but also because they are sometimes being used by young men
without ED to enhance sexual performance for recreational pur-
poses, occasionally associated with the intake of alcohol or other
drugs (Korkes and others 2008; Bechara and others 2010). Even
though these substances are considered as controlled prescription
drugs, for several reasons including the stigma associated with
sexual dysfunction and/or personal lack of confidence to openly
speak with the doctor, lack of information, drug costs, and avail-
ability from easily accessible, cheaper, and discrete sources such as
Internet Web sites, the supply of these products without medical
prescription through unofficial methods/parallel markets has been
increasing during the last decade (Campbell and others 2013; Fejos
and others 2014; Patel and others 2014). It is estimated that in Eu-
rope alone more than 6 million illegal products containing PDE-5
inhibitors are being purchased outside the official health system
(Schnetzler and others 2010; Venhuis and de Kaste 2012) and that
in the United States more than half a million of such uncontrolled
tablets are being sold every month (Dorsey and Hellstrom 2007).
Since these counterfeit products are not under any quality control
program, there is an inherent risk of buying a poor-quality product,
for example, having impurities, lacking sample homogeneity, or
incorrect dosage. Besides the problematic use of counterfeit phar-
maceutical products, several recent studies have shown the illegal
presence of PDE-5 inhibitors and/or its analogs in PFS (Table 3).
These types of supplements are increasingly popular since they are
advertised as "natural products" for sexual performance enhance-
ment leading to a false sense of security in consumers (Liang and
others 2006; Singh and others 2009; Campbell and others 2013;
Fejos and others 2014). Since the existence of demand leads to a
rise in supply, a growing number of products have recently been
advertised on the Internet and on television, usually marketed as
a "natural" resolution for sexual problems (Liang and others 2006;
Singh and others 2009; Petroczi and others 2011; Strano-Rossi and
others 2015). However, to boost the performance of such prod-
ucts, unscrupulous producers can dope PFS with PDE-5 inhibitors
(Table 3). Since 2010, FDA issued 229 public notifications for
sexual enhancement dietary supplements (corresponding to
more than 55% of total public notifications regarding dietary
supplements for that period) due to the positive detection of
approved PDE-5 inhibitors or its analogs (mainly sildenafil,
but also tadalafil and the analogs sulfoaildenafil, aminotadalafil,
hydroxythiohomosildenafil, sulfosildenafil; dimethylsildenafil, sul-
fohydroxyhomosildenafil, dimethylacetildenafil, noracetildenafil,
desmethyl carbodenafil, desmethylcarbondenafil, sulfosildenafil,
and propoxyphenyl sildenafil). In the same period, 81 notifica-
tions were issued by RASFF regarding the presence of PDE-5
inhibitors or their analogs in dietetic foods, food supplements,
and fortified foods.
Adulterated sexual enhancement PFS impose a very high risk
to consumers’ health as they are buying and consuming products
that can cause adverse health effects, in particular in the case of
individuals with cardiovascular diseases medicated with nitrates or
α-blockers (Champagne and Emmel 2011; Venhuis and de Kaste
2012). As those individuals are advised not to take PDE-5 in-
hibitors, they can be tempted to try other alternatives advertised
as being natural products and inadvertently put their lives at risk
due to drug interactions caused by the adulterated PFS. Moreover,
according to Venhuis and de Kaste (2012) PFS are most frequently
adulterated with analogs rather than with approved PDE-5 drugs.
These analogs are generally synthesized based on the PDE-5 ap-
proved drugs, with minor changes on their structures, with some
analogs also corresponding to substances described in patents from
pharmaceutical companies (Venhuis and de Kaste 2012). These
unapproved analogs raise additional safety concerns as their phar-
macokinetics and safety profile are mostly unknown. On the other
hand, from the point of view of manufacturers performing PFS
adulteration, the use of new and exotic analogs reduces the chances
of being caught as these substances are generally more difficult to
be detected in routine inspections using standard protocols (Patel
and others 2014). Therefore, to protect consumers from fraudulent
products, adequate methods for dietary supplements monitoring,
including screening methods, strategies for the identification of
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new and unapproved compounds, and quantification of adulter-
ants, are considered to be essential tools (Singh and others 2009;
Fejos and others 2014; Johansson and others 2014; Patel and others
2014; Strano-Rossi and others 2015).
Determination of Adulterating Substances
The selection of sample preparation methodologies, as well as
the analytical technique chosen for detection, identification and,
eventually, quantification of the substances of interest, depends on
several factors including the number of targeted compounds and
different chemical families they belong to, required sensitivity, for-
mulation type (tablets, oily capsules, liquids, and so on) and the
complexity of the matrix (for example, some samples include a
large number of different botanicals in their composition). In the
following sections, an overview of different methodologies used
for detecting synthetic adulterants in dietary supplements, focus-
ing on various PFS, namely weight loss, muscle building/sport
performance, and sexual enhancement performance is presented.
Extraction methods/sample preparation
As can be observed in Table 1 to 3, which show several studies
that include the analysis of PFS samples aiming for the detection of
illegally added synthetic drugs, most sample preparation methods
generally comprise the extraction of analytes using an organic sol-
vent, such as methanol or acetonitrile or their aqueous mixtures,
with the obtained solution/suspension being agitated (shaking,
vortex-mixed) or sonicated, centrifuged, further diluted, and fil-
tered. Liquid samples are often simply diluted with the solvent,
filtered, and directly injected for analysis. Despite the simplicity
and fastness of such sample preparation methodologies, consider-
ing the matrix complexity several different phytochemicals can be
co-extracted, which can influence the determination of the ana-
lyte(s) of interest. Therefore, besides simple extraction methodolo-
gies, clean-up procedures, and/or preconcentration steps maybe
required depending on the detection technique used for analyz-
ing the extract. In particular, when mass spectrometry (MS) is
used co-extracted matrix components can potentially interfere
with the detection of target analytes and cause severe matrix ef-
fects during electrospray ionization (ESI) either inducing suppres-
sion or enhancement of the signal, thus impairing the accuracy
of the analysis (Vaclavik and others 2014a, 2014b). Matrix ef-
fects are generally minimized by using hyphenated techniques,
namely, through the previous separation of compounds by chro-
matography. Additionally, the use of optimized sample extraction
and clean-up protocols has been suggested by different authors,
including the use of liquid-liquid extraction (Geyer and others
2008; Schramek and others 2014; Strano-Rossi and others 2015),
solid-phase extraction (SPE) (Stepan and others 2008; Peters and
others 2010; Becue and others 2011), and QuEChERS (quick,
easy, cheap, effective, rugged, and safe) procedure (Vaclavik and
others 2014a). When analyzing 88 steroid compounds in PFS us-
ing ultra-performance liquid chromatography-MS (UPLC-MS),
Becue and others (2011) concluded that a clean-up procedure
using a SPE NH2-column was necessary for improved sensitiv-
ity and selectivity, since it allowed for a substantial reduction of
background noise by retention of polar matrix effects. Stepan and
others (2008) employed dispersive SPE using primary secondary
amine (PSA) as a sorbent to effectively remove polar compo-
nents such as sugars, 4-hydroxy-2-methoxycinnamaldehyde and
partially remove fatty acids and vanillin. More recently, Vaclavik
and others (2014a) used a QuEChERS procedure to extract target
analytes from PFS samples. The QuEChERS procedure is based
on sample extraction using a mixture of acetonitrile and water
and subsequent separation of phases by the addition of salts, with
the polar matrix components being retained in the aqueous phase,
while the analytes of interest are transferred to the organic phase.
The employed procedure allowed an effective extraction of most
analytes from the evaluated matrices with recoveries in the range
of 80% to 120%, with the exception of highly polar analytes as
they have more affinity for the aqueous phase. For the clean-up
and purification of oily matrices from softgels, defatting with hex-
ane and the use of a dispersive SPE purification step with Bondesil
C18 (octadecylsilane) sorbent showed to be effective, since it en-
abled the removal of some nonpolar co-extractants and slightly
decreased the matrix effects while not decreasing recoveries of the
analytes (Vaclavik and others 2014a).
Additionally to extraction, depending on the used technique, it
can be necessary to include a derivatization reaction step during
sample preparation. In the case of gas chromatography-MS (GC-
MS) detection methods, still frequently used for the detection of
steroids and prohormones, considering the poor volatility of most
adulterants, derivatization is most often needed, which slightly
increases total sample preparation time (Geyer and others 2008;
Vaclavik and others 2014b).
Techniques used for the detection and identification
of adulterants
Chromatographic methods. Thin-layer chromatography (TLC).
TLC has long been used in the characterization of plant drugs
with pharmacologically active components in botanical formula-
tions and standardized extracts. TLC can also be used for the pre-
liminary identification of herbal products adulterated with phar-
macological drugs (Cai and others 2010; Csupor and others 2013).
TLC is considered to be a simple, easy, rapid, and inexpensive
technique for the preliminary screening of compounds, however
the availability of standards for those substances is mandatory and,
above all, it has a very low sensitivity (Ariburnu and others 2012).
Recently, Lv and others (2015) proposed a method which com-
bined TLC and surface-enhanced Raman scattering (SERS) to
directly identify stimulant alkaloids (ephedrine, pseudoephedrine,
methylephedrine, and norephedrine) as trace adulterants in PFS.
The method used SERS technology which relies on the specific
vibrational spectroscopy with ultra-high sensitivity at molecular
level based on 8 common Raman peaks for the compounds under
evaluation. This allowed for a simple, rapid, and accurate method-
ology, with results from real samples analysis being confirmed by
UPLC quadrupole time of flight MS (UPLC-QTOF/MS).
The use of high-performance TLC (HPTLC) also allows im-
proving sensitivity compared to TLC, thus it has already been
reported as a screening method for herbal products adulterated
with pharmacological drugs (anorectic and PDE-5 inhibitor drugs)
(Abourashed and others 2007; Sanzini and others 2011; Ariburnu
and others 2012). Recently, Mathon and others (2014) proposed
an HPTLC-ultraviolet (UV) densitometric method for the quan-
tification of sibutramine in PFS, with its unequivocal identification
being confirmed by MS using a TLC-MS interface. The method
was applied to the analysis of 52 weight-loss supplements obtained
via the Internet showing that half of those were adulterated with
sibutramine, with some products containing amounts 3 times
higher than the dosage prescribed as an appetite suppressant
drug prior to its withdrawal (Mathon and others 2014). The
authors reported the nonexistence of significant statistical differ-
ences among the quantitative results obtained using the validated
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HPTLC method with those obtained by HPLC-UV and HPLC-
MS/MS.
Irrespectively of the PFS type (weight loss, muscle building, or
sexual performance), since in both methods (TLC and HPTLC),
reference standards are required for a positive identification, they
are not considered appropriate for screening adulterations with
new pharmacological drugs (designer drugs).
High-performance liquid chromatography (HPLC). HPLC is a well-
established and widespread technique for the routine analysis of
different compounds all over the world (De Carvalho and others
2011). In the case of complex matrices, such as PFS, the chro-
matographic step prior to analyte detection/identification enables
the separation of several phytochemicals from the bulk sample
matrix that could interfere or suppress the signals of the com-
pounds of interest (Vaclavik and others 2014a, 2014b). Liquid
chromatography (LC), namely HPLC and more recently ultra-
high-performance LC (UHPLC), is the most commonly reported
separation technique applied for the analysis of pharmaceuti-
cal adulterants in dietary supplements, in particular those used
for weight loss and sexual performance enhancement (Table 1
and 3). The use of HPLC coupled to ultraviolet detection, espe-
cially HPLC with a diode array detector (DAD), has been rec-
ognized for the preliminary identification and screening of adul-
terants in weight-loss products (De Cock and others 2001; De
Carvalho and others 2011; Deconinck and others 2012a; Rebiere
and others 2012; Csupor and others 2013) and sexual PEDs (Singh
and others 2009; Ortiz and others 2010; Savaliya and others 2010;
Sacre´ and others 2011; Venhuis and others 2011a, 2011b; Wollein
and others 2011; Jankovics and others 2013; Fejos and others
2014; Zhang and others 2014). HPLC-UV has also been used in
semipreparative chromatography for unknown compounds isola-
tion purposes (Lee and others 2011). When using HPLC-DAD,
the screening and detection of compounds is based on information
of UV spectra and retention time compared to those obtained for
pure standards. Thus, although being simpler and cost-effective
compared to other techniques, HPLC-DAD has limited applica-
bility, especially in the case of new analogs/designer drugs, for
which no standards are available. Nevertheless, in some cases, this
technique can still assist researchers in the preliminary detection of
such adulterants, namely those analogs structurally similar to the
original compound, as they will present different retention times
but identical UV spectra (Hou and others 2006).
In the last decade, LC coupled to MS detection has become a
primary tool in the analysis of adulterants in PFS, since it combines
the separation capacity of LC with the sensitivity and selectivity
of MS detectors allowing for molecular identification (Patterson
and others 2012; Vaclavik and others 2014a, 2014b). When stan-
dards are available, the use of LC preceding MS analysis also con-
tributes to the identification of compounds based on its retention
time. The use of LC-MS for the elucidation of adulterant struc-
tures in food supplements, detailing different MS detectors (en-
abling low or high resolution mass measurements), different data
acquisition modes, and potential application in posttargeted and
nontargeted screening approaches, has been recently reviewed by
Vaclavik and others (2014a, 2014b). Currently, LC-MS is consid-
ered by most researchers as being the method of choice to detect
pharmaceutical adulterants in PFS, with several works available in
the literature concerning the analysis of dietary supplements for
weight loss and sexual performance enhancement, as described in
Table 1 and 3, respectively. Regarding muscle building/sport en-
hancement food supplements, GC-MS has been intensively used
over the last decades for the analysis of nondeclared doping sub-
stances added to those products (Becue and others 2011). How-
ever, more recently, several laboratories are adopting LC-MS as a
valuable tool for this type of analysis since it generally requires a re-
duced sample treatment compared to GC-MS and allows detecting
thermolabile compounds (Becue and others 2011). Nevertheless,
a major disadvantage for LC-MS is that a general searchable mass
spectral library, such as the Natl. Inst. for Standards and Testing
(NIST) for GC-MS, is not available for LC-MS (Becue and others
2011; Peters and others 2010). Still, since accurate high-resolution
mass measurements are specific for every compound regardless of
the instrumentation used, potentially these data could enable the
use of accurate mass databases for compound identification (Peters
and others 2010).
Gas chromatography (GC). Despite being a sensitive, repro-
ducible, accurate, and quantitative technique, well suited for the
analysis of mixtures, and of lower cost compared to LC-MS, GC
methodologies are rarely used for the analysis of the most fre-
quently found pharmaceutical adulterants in dietary supplements,
with a general exception being the detection of anabolic steroids
in muscle building supplements, which is frequently accomplished
using GC-MS.Other examples of GC applications are the works of
Marchei and others (2006) and Man and others (2009). The main
criterion that should be considered when using GC methodolo-
gies is the volatility and thermal stability of the compounds. This
can explain the low usage of GC methods in the analysis of PDE-5
inhibitors and their analogs, as they are considered to be heat-labile
and difficult to derivatize using standard silylation reagents (Patel
and others 2014). Nevertheless, in certain cases where the LC-MS
technique does not provide sufficient information for compound
identification, the analysis of chemical reaction products (such as
hydrolysis products) by GC-MS has been described as a useful
complementary tool for structure elucidation and identification
of designer drugs as, for example, new PDE-5 inhibitors analogs
(Patel and others 2014; Vaclavik and others 2014a, 2014b)
Despite being a sensitive, reproducible, accurate, and quanti-
tative technique, well suited for the analysis of mixtures, and of
lower cost compared to LC-MS, GC methodologies are rarely
used for the analysis of the most frequently found pharmaceutical
adulterants in dietary supplements, with a general exception being
the detection of anabolic steroids in muscle building supplements,
which is frequently accomplished using GC-MS. Other examples
of GC applications are the works of Marchei and others (2006) and
Man and others (2009). The main criterion that should be consid-
ered when using GC methodologies is the volatility and thermal
stability of the compounds. This can explain the low usage of GC
methods in the analysis of PDE-5 inhibitors and their analogs, as
they are considered to be heat-labile and difficult to derivatize
using standard silylation reagents (Patel and others 2014). Nev-
ertheless, in certain cases where the LC-MS technique does not
provide sufficient information for compound identification, the
analysis of chemical reaction products (such as hydrolysis prod-
ucts) by GC-MS has been described as a useful complementary
tool for structure elucidation and identification of designer drugs
as, for example, new PDE-5 inhibitors analogs (Patel and others
2014; Vaclavik and others 2014a, 2014b).
In the case of muscle building/sport performance dietary sup-
plements, the substances most probably used as adulterants are
prohormones and steroids. GC-MS has long been routinely used
in the analysis of such compounds as doping agents in sports, be-
ing also suited for PFS analysis. Since GC-MS uses standardized
and universal electron impact ionization (EI) conditions, similar
spectra are obtained for the same compound, even when using
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different equipment, thus allowing the use of standard reference
databases such as NIST (Becue and others 2011). Nevertheless,
this technique requires a derivatization step, generally trimethylsi-
lylation, which makes sample preparation more cumbersome and
time-consuming. Recently, a method based on comprehensive
2-dimensional (2D) gas chromatography (GC × GC) with TOF-
MS detection for the determination of 25 anabolic steroids in food
supplements was proposed by Stepan and others (2008). Contrar-
ily to most other GC-MS techniques, this technique does not
require derivatization. Moreover, it allows obtaining lower lim-
its of detection, achieving enhanced chromatographic resolution,
and complete separation of target steroids as a result of separation
being performed in 2 capillary columns with different polarities,
thus reducing the risk of false positives (Stepan and others 2008).
Mass spectrometry. MS is the most applied detection method
for the identification and structural elucidation of adulterants in
dietary supplements as it fulfills the requirements of selectivity and
sensitivity needed for such analyses. With technology evolution,
there are currently several different types of MS detectors available,
which are frequently used in hyphenated techniques, including
single quadruple, triple quadrupole, linear trap, Orbitrap (Fourier
transform MS), Fourier transform ion clyclotron resonance MS
(FT-ICR-MS) and time of flight (TOF), among others. MS can
be rearranged to a tandem (MS/MS) or a multistage (MSn) MS,
improving its accuracy and resolution (Patel and others 2014).
Apart from its extensive use in hyphenated techniques,
direct-infusion MS has also been reported in several works,
mainly for structural identification purposes applied to isolated
and purified compounds. Direct-infusion MSn and collision-
induced dissociation (CID) MS experiments have been used to
provide useful information on the structural elucidation of new
analogs of vardenafil and sildenafil, namely piperidenafil and
nor-acetildenafil (Reepmeyer and Woodruff 2006, 2007). Ahn
and others (2009) proposed the use of high-resolution MS and
fast-atom bombardment coupled to high-energy CID tandemMS
(FAB-CID-MS/MS) to elucidate the structures of sildenafil and
its analogs isolated from food supplements. Direct infusion or flow
injection MS (FI-MS) has also been proposed as an analytical tool
to detect adulterants in different samples, including those added
to PFS. FI-MS allows complex mixtures to be resolved into com-
ponents differing in ion mass and has the advantage of being a fast
and high-throughput approach since it does not involve any prior
time-consuming LC separation (Koulman and others 2007). Nev-
ertheless, a higher extent of matrix effects is generally observed in
FI-MS compared to hyphenated MS techniques (Vaclavik and
others 2014a, 2014b). Song and others (2012) reported the use
of FI-MS with a triple quadrupole operating in multiple reaction
monitoring (MRM) mode to screen for PDE-5 inhibitors in food
supplements. The authors reported some difficulties in identifying
some similar analogs (homosildenafil, hydroxyhomosildenafil,
and sulfoaildenafil) as they shared both precursor and products
ions. Identical difficulties were reported for a FI tandem MS
(FI-MS/MS) with MRM monitoring applied for the semiquan-
titative screening of weight-loss drugs, namely phenolphthalein,
sibutramine, and its pharmacologically active metabolites
N-desmethylsibutramin and N-didesmethylsibutramine, in
17 food supplements (Song and others 2014). The authors
reported that FI-MS/MS offered an improved sensitiv-
ity, selectivity, and wider detection ranges, although N-
formyldidesmethylsibutramine could be assigned mistakenly as
sibutramine based on FI-MS/MS analysis alone, as they give
similar product ion profiles and ion ratio for the 3 commonMRM
transitions used. In this study, FI-MS/MS allowed the detection of
11 positive samples for sibutramine and 9 samples for phenolph-
thalein, which were further confirmed by LC-MS/MS. Other
reported applications used a hierarchical approach in which ESI-
MS fingerprinting is followed by the targeted analysis of specific
m/z signals by high resolution methods (Draper and others 2013).
Spectroscopic methods. Even though hyphenated methodolo-
gies using MS detection are undoubtedly considered as the most
used and adequate methodologies for the determination of phar-
maceutical drugs and their analogs illegally added in food supple-
ments, recently, there has been an increased interest on the use
of spectroscopic methods as they are rapid, have high through-
put, are simple to use, require little or no sample preparation,
and can be possibly adapted for on-field screening. For those rea-
sons, spectroscopic methods have been suggested as feasible and
interesting screening tools to be used by inspectors and customs,
which are frequently confronted with a large number of products
suspected of being adulterated that must be confiscated and sent to
a laboratory for analysis inspection (Deconinck and others 2014).
Among spectroscopic methods, vibrational spectroscopic
methods, such as infrared (IR), near infrared (NIR) or Raman
spectroscopy have already been used to detect counterfeit phar-
maceuticals (Sacre´ and others 2010; Deconinck and others 2012b)
and have shown usefulness for the authentication of different
food matrices (Rodriguez-Saona and Allendorf 2011; Liu and
others 2013; Rohman and others 2014). Fourier transform IR
spectroscopy (FTIR) is frequently associated with attenuated
total reflectance (ATR) sampling enabling samples to be analyzed
directly with no need for sample preparation. Champagne and
Emmel (2011) proposed the use of FTIR-ATR operating in the
mid-infrared region (4000 to 650 cm−1) to screen adulterations
in raw materials used in the formulation and manufacture of food
supplements. With this aim, the authors selected 84 raw ingredi-
ents (including different botanical materials, amino acids, proteins,
polysaccharides, among others) used in food supplements formu-
lations, which were analyzed before and after being spiked with
appropriate adulterants (sildenafil, vardenafil, tadalafil) or adulter-
ant surrogates (progesterone, a metabolite of DHEA, glutamine,
niacinamide, tyrosine, and melamine). The Compare Function
in AssureID software from PerkinElmer was used for spectral
comparisons and further calculating correlation thresholds,
disregarding band intensity or amplitude and considering shape
only, thus allowing automation by providing a “pass” or “fail”
report. The lowest level of adulteration needed to create a “fail”
report was set by serially adulterating 4 selected raw materials with
increasing amounts of adulterant. The proposed method proved to
be fast, easy to do, and not requiring expertise technicians; it is thus
suited for on-field screening. Still, criticism of this work concerns
the extrapolation of results since, with the exception of PDE-5
inhibitors, surrogates with similar structure were used instead of
the adulterant substances themselves. Additionally, the proposed
method has a short applicability since it only allows testing raw
materials, because, as mentioned by the authors, the obtained
detection limits would be unacceptable for finished product
screening. More recently, Deconinck and others (2014) suggested
the use of ATR-IR spectra combined with k-nearest neighbors
chemometrics for the detection of sibutramine in adulterated food
supplements. The authors analyzed a set of 125 food supple-
ments suspected of being adulterated (products were previously
evaluated for the presence of sibutramine) and concluded that
FTIR-ATR was able to detect all the adulterated products, with
a minimum of false positives. The authors suggested its possible
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use as a screening tool since no adulterated samples would pass
the customs inspection and the possible cases of false positives,
although resulting in products being retained, would be clarified
after laboratory analysis.
Vibrational spectroscopy methodologies have also been used in
conjunction with other techniques, such as accurate MS, X-ray
crystallography, and nuclear magnetic resonance (NMR) spec-
troscopy, for the identification and structural elucidation of new
adulterants in PFS. The use of FTIR has also been described as
an additional tool in the identification of different analogs iso-
lated from food supplements such as thiosildenafil (Vaysse and
others 2012), nitroso-prodenafil (Venhuis and others 2011b),
propoxyphenyl aidenafil, and methiososildenafil (Kee and others
2012), while NIR spectroscopy and Raman spectroscopy proved
useful in detecting Rimonabant polymorphs (Venhuis and others
2011b).
Besides being considered a crucial tool for structural identifi-
cation of new analogs (Zou and others 2008; Balayssac and others
2012) or other new compounds used as PDE-5 inhibitors (Ge
and others 2008), the use of NMR spectroscopy has also been
described for the detection and quantification of adulterants in
PFS. NMR is considered a robust technique, highly reproducible,
requiring minimum sample preparation, and with no need for
reference standards (Martino and others 2010; Johansson and
others 2014). Other referred advantages concern the improvement
of sensitivity in recent NMR equipment and the possibility of
using 1HNMR for quantitative purposes (Balayssac and others
2009; Johansson and others 2014). Moreover, the use of advanced
techniques that are able to provide global information, such as 2D
diffusion ordered spectroscopy 1H NMR (2D DOSY 1H NMR),
or 3-dimensional (3D) DOSY–COSY 1H NMR, enables the
analysis of various compounds in complex matrices in a single
run, since those methods are nonselective and do not require prior
knowledge of the components present in the mixture (Balayssac
and others 2009; Vaysse and others 2012). Balayssac and others
(2009) used conventional 1HNMR, 2DDOSY 1HNMR and 3D
DOSY–COSY 1H NMR to analyze 17 commercial herbal drugs
or food supplements marketed for sexual dysfunction and found 8
of those samples to be illegally augmented with PDE-5 inhibitors
or respective analogs, namely sildenafil, tadalafil, vardenafil,
hydroxyhomosildenafil, thiosildenafil, and the newly identified
adulterant thiomethisosildenafil. Most recently, Gilard and others
(2015) analyzed a total of 150 food supplements advertised as
being natural products for sexual performance enhancement
and concluded that 92 of those samples (corresponding to 61%)
were adulterated with PDE-5 inhibitors or its analogs. The
authors also reported the presence of flibanserin, an experimental
drug for the treatment of hypoactive sexual desire disorder in
women, in 2 samples and steroidal hormones (testosterone and
DHEA) in 5 samples. Besides PDE-5 inhibitor drugs and/or its
analogs, detection of the anorexic drug sibutramine, the stimulant
synephrine and the laxative phenolphthalein have also been
detected in food supplements by using NMR (Vaysse and others
2010). Recently, the use of NMR spectroscopy in combination
with LC–QTOF-MS also allowed detecting sibutramine, orlistat,
sildenafil, fluoxetine and/or yohimbine in 21 weight-loss food
supplements (Johansson and others 2014).
Other methods. The use of bioassays, such as the estrogen and
androgen mammalian reporter gene assays (RGAs) and the yeast
androgen bioassay, have been suggested as a general screening
procedure to detect steroids in sports dietary supplements (Rijk
and others 2009; Plotan and others 2012). These bioassays present
several advantages, such as high sensitivity and lower cost, com-
pared to methods that require the use of advanced and expensive
equipment, as well as high throughput as they screen samples for
a large group of compounds presenting similar biological effects.
However, they generally are comprised of lengthy analysis, they
can give inconclusive results due to toxic effects generated by
the extracts, and, above all, they are unable to identify steroid
compound(s), thus requiring confirmation analyses by using tech-
niques that allow for identification (Peters and others 2010; Becue
and others 2011). In this regard, Peters and others (2010) proposed
the use of a bioassay-guided fractionation based on a recombinant
yeast androgen bioassay and further analysis by UHPLC/TOF-
MS of the positive fractions to confirm and identify unknown
androgens in food supplements. The authors also tested the
possibility of directly analyzing the samples by UHPLC/TOF-MS
without previous bioassay-guided fractionation, and they con-
cluded that, although it allowed to tentatively identify androgens
and their derivatives in samples of sport food supplements, the
method was much more laborious since many compounds are
identified and have to be screened as potential adulterants (Peters
and others 2010). More recently, Aqai and others (2013) proposed
a novel bioaffinity liquid chromatography-MS (BioMS) method
for screening and identification of designer anabolic steroids in
dietary supplements. The bioaffinity assay was developed for
molecules binding to the recombinant human sex hormone-
binding globulin (rhSHBG), with the possibility of using the
same biopurified extract for subsequent compound identification
using chip-ultra-performance-LC(NanoTile)-quadrupole-time-
of-flight MS (chip-UPLC-Q-ToF-MS) with full scan accurate
mass measurement. The authors suggested that this would be a
powerful tool for early detection of emerging unknown designer
steroids in food supplements, thus contributing to fight doping in
sports (Aqai and others 2013).
Conclusions
Following the current legislation in EU countries and the U.S.,
dietary supplements (including PFS) are not subjected to any
specific regulatory preapproval requirements or safety assessments
prior to commercialization. This allows for unscrupulous man-
ufacturers and distributors to deliberately adulterate supplements
through the addition of pharmaceutical drugs or analogue
substances (designer drugs, often not characterized for their
efficacy or toxicity) in order to increase product effectiveness.
However, consumers are not aware of such possibilities and cases
of drug interactions and deleterious health effects can occur.
Thus, with the growing consumption of these products, with
special emphasis on PFS, and market globalization, there is
also an increased need for more effective control by competent
authorities in order to detect possible adulterations and, in such
cases, take enforcement measures to safeguard public health.
Therefore, the development of new and improved analytical
methodologies for the detection and structural identification
of adulterants from different pharmacological classes (including
new/unknown analogs) is critically important to protect public
health and ensure the quality of dietary supplements.
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